Supplement Slows Prostate Cancer Indicator in Clinical Trial
A supplement is showing promise in slowing the progression of prostate cancer, according to findings from a recent clinical trial. The results offer a potential new avenue for managing the disease, which affects millions of men worldwide. Prostate cancer remains a significant public health concern, and new treatment options are continually being explored.
The study, published in the scientific journal “BJUI International,” details a new generation of medical technologies specifically designed to combat prostate cancer. The trial, known as “ProFocal laser therapy for the ablation of prostate tissue,” is the first and unique study of the “ProFocal” device.
The ProFocal device utilizes a precisely targeted, cooled laser technology to treat cancerous cells directly, while working to protect the remaining healthy parts of the prostate gland from radiation or surgical damage. This makes it a potentially preferred option for a specific group of patients seeking focal treatment solutions that concentrate on the affected area only.
Researchers indicated that the technology represents a medical innovation in the fight against prostate cancer. The findings could lead to more targeted and less invasive treatment options for some patients.
